X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SUN PHARMA - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SUN PHARMA BIOCON /
SUN PHARMA
 
P/E (TTM) x 41.0 27.7 148.1% View Chart
P/BV x 7.1 2.9 244.1% View Chart
Dividend Yield % 0.2 0.4 37.6%  

Financials

 BIOCON    SUN PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
SUN PHARMA
Mar-18
BIOCON /
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188701 169.6%   
Low Rs305433 70.4%   
Sales per share (Unadj.) Rs68.7110.4 62.2%  
Earnings per share (Unadj.) Rs7.611.0 68.8%  
Cash flow per share (Unadj.) Rs14.017.2 81.1%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.4 38.0%  
Book value per share (Unadj.) Rs86.3158.8 54.4%  
Shares outstanding (eoy) m600.002,399.26 25.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.95.1 211.6%   
Avg P/E ratio x98.951.6 191.4%  
P/CF ratio (eoy) x53.432.9 162.4%  
Price / Book Value ratio x8.63.6 242.2%  
Dividend payout %13.218.2 72.7%   
Avg Mkt Cap Rs m447,9001,360,021 32.9%   
No. of employees `0006.117.8 34.6%   
Total wages/salary Rs m9,31153,671 17.3%   
Avg. sales/employee Rs Th6,705.814,890.9 45.0%   
Avg. wages/employee Rs Th1,514.23,017.1 50.2%   
Avg. net profit/employee Rs Th736.91,480.6 49.8%   
INCOME DATA
Net Sales Rs m41,234264,895 15.6%  
Other income Rs m2,0628,388 24.6%   
Total revenues Rs m43,296273,282 15.8%   
Gross profit Rs m8,29156,081 14.8%  
Depreciation Rs m3,85114,998 25.7%   
Interest Rs m6155,176 11.9%   
Profit before tax Rs m5,88744,295 13.3%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m1,5698,452 18.6%   
Profit after tax Rs m4,53126,338 17.2%  
Gross profit margin %20.121.2 95.0%  
Effective tax rate %26.719.1 139.7%   
Net profit margin %11.09.9 110.5%  
BALANCE SHEET DATA
Current assets Rs m41,486316,359 13.1%   
Current liabilities Rs m21,413198,643 10.8%   
Net working cap to sales %48.744.4 109.5%  
Current ratio x1.91.6 121.7%  
Inventory Days Days6495 67.5%  
Debtors Days Days94108 87.5%  
Net fixed assets Rs m50,661213,178 23.8%   
Share capital Rs m3,0002,399 125.0%   
"Free" reserves Rs m48,808378,606 12.9%   
Net worth Rs m51,808381,006 13.6%   
Long term debt Rs m17,89817,721 101.0%   
Total assets Rs m99,897643,028 15.5%  
Interest coverage x10.69.6 110.6%   
Debt to equity ratio x0.30 742.8%  
Sales to assets ratio x0.40.4 100.2%   
Return on assets %5.24.9 105.1%  
Return on equity %8.76.9 126.5%  
Return on capital %9.610.0 96.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05840,816 29.5%   
Fx outflow Rs m7,34830,143 24.4%   
Net fx Rs m4,71010,673 44.1%   
CASH FLOW
From Operations Rs m6,62139,072 16.9%  
From Investments Rs m-6,840-33,708 20.3%  
From Financial Activity Rs m-2,397-15,393 15.6%  
Net Cashflow Rs m-2,612-7,359 35.5%  

Share Holding

Indian Promoters % 40.4 63.7 63.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.1 163.7%  
FIIs % 10.7 23.0 46.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.3 239.8%  
Shareholders   109,995 133,026 82.7%  
Pledged promoter(s) holding % 0.0 0.5 7.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   PLETHICO PHARMA  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 18, 2019 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS